newsfilter
← Latest News
PR Newswire·

Seelos Therapeutics Doses First Patient in an Open Label Basket Study of SLS-005 in Amyotrophic Lateral Sclerosis in Australia and Provides an Enrollment Update of its Study on the HEALEY ALS Platform

SLS-005 Study on the HEALEY ALS Platform is Expected to Complete Enrollment this Quarter; Top-Line Data Readout Expected Mid-2023 NEW YORK, July 18, 2022 /PRNewswire/ -- Seelos Therapeutics, Inc. (NASDAQ:SEEL), a clinical-stage biopharmaceutical compan